Zydus Amplitude's Robotic Surgical System 'Andy' Receives CE Mark Approval for European Market
Key Insights
Amplitude Surgical (search), a subsidiary of Zydus Lifesciences, has received CE mark approval for its robotic surgical system 'Andy', confirming compliance with European safety and quality standards.
The system integrates proprietary Amplivision navigation technology with robotic assistance to perform bone resections with enhanced precision and reliability.
Andy is designed to minimize tissue trauma, resulting in smaller incisions, reduced pain, faster recovery, and improved long-term implant performance for orthopedic procedures.
Amplitude Surgical (search), a wholly owned subsidiary of Zydus Lifesciences Ltd, has announced that its robotic surgical system "Andy" has received CE mark approval, confirming its compliance with European standards for safety, performance, and quality. This regulatory milestone enables the company to market the advanced surgical robot across European markets.
Advanced Navigation Technology Integration
Andy is built with Amplitude's proprietary navigation platform, Amplivision, which integrates the company's navigation technology with robotic assistance. The system was developed through a strategic collaboration with eCential Robotics (search), combining expertise in surgical navigation and robotic technologies.
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Ltd, commented on the achievement: "This milestone reflects our commitment to innovation that is both patient-centric and future-ready. Andy represents a convergence of science, healthcare, and technology, I extend my heartfelt congratulations to the Amplitude R&D team for their unwavering dedication and scientific excellence in bringing this breakthrough to life."
Precision Surgical Capabilities
Andy functions as a collaborative robot built on proprietary technology capable of performing bone resections with precision and reliability. The system delivers enhanced accuracy and consistency, enabling optimal alignment while minimizing tissue trauma during orthopedic procedures.
The robotic system is designed to provide several clinical benefits, including smaller incisions, reduced pain, faster recovery, and fewer complications. These improvements are intended to enhance knee function, shorten hospital stays, and ensure long-term implant performance for patients undergoing orthopedic surgery.
Strategic Expansion in Orthopedic Technology
The CE mark approval follows Zydus MedTech (search)'s strategic acquisition of Amplitude Surgical (search) earlier this year, expanding the company's global presence in the medical technology sector. Amplitude Surgical specializes in high-quality lower-limb orthopedic technologies, positioning the combined entity to compete in the advanced surgical robotics market.
Zydus Lifesciences Ltd operates as a global life sciences company that discovers, develops, manufactures, and markets healthcare therapies across multiple therapeutic areas. Over the past decade, the company has introduced several products addressing unmet healthcare needs, including vaccines, therapeutics, biologicals, and new chemical entities.